A number of other equities analysts have also weighed in on ZYNE. Cantor Fitzgerald set a $32.00 target price on Bausch Health Companies and gave the stock a buy rating in a research note on Friday, May 31st. ValuEngine lowered Zumiez from a hold rating to a sell rating in a research note on Tuesday, July 2nd. Zacks Investment Research lowered Zynerba Pharmaceuticals from a buy rating to a hold rating in a research note on Saturday, June 8th. LADENBURG THALM/SH SH restated a buy rating and issued a $26.00 target price on shares of Zynerba Pharmaceuticals in a research note on Thursday, May 30th. Finally, Roth Capital upped their target price on Shopify from $275.00 to $225.00 in a research note on Tuesday, April 30th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Zynerba Pharmaceuticals has a consensus rating of Buy and an average price target of $22.00.
Shares of NASDAQ ZYNE opened at $13.64 on Thursday. Zynerba Pharmaceuticals has a one year low of $2.75 and a one year high of $16.47. The company’s fifty day moving average price is $13.16. The stock has a market cap of $303.48 million, a PE ratio of -5.23 and a beta of 4.86.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. On average, equities analysts predict that Zynerba Pharmaceuticals will post -2.04 earnings per share for the current year.
Institutional investors have recently made changes to their positions in the company. Bernardo Wealth Planning LLC boosted its position in Zynerba Pharmaceuticals by 5.3% during the 1st quarter. Bernardo Wealth Planning LLC now owns 25,419 shares of the company’s stock worth $138,000 after acquiring an additional 1,278 shares during the last quarter. Virtu Financial LLC boosted its position in Zynerba Pharmaceuticals by 66.9% during the 1st quarter. Virtu Financial LLC now owns 22,384 shares of the company’s stock worth $121,000 after acquiring an additional 8,970 shares during the last quarter. Campbell Capital Management Inc. boosted its position in Zynerba Pharmaceuticals by 5.3% during the 1st quarter. Campbell Capital Management Inc. now owns 180,787 shares of the company’s stock worth $980,000 after acquiring an additional 9,100 shares during the last quarter. Deutsche Bank AG boosted its position in Zynerba Pharmaceuticals by 17,314.3% during the 4th quarter. Deutsche Bank AG now owns 279,500 shares of the company’s stock worth $830,000 after acquiring an additional 277,895 shares during the last quarter. Finally, Two Sigma Investments LP acquired a new position in Zynerba Pharmaceuticals during the 4th quarter worth approximately $120,000. Hedge funds and other institutional investors own 10.94% of the company’s stock.
About Zynerba Pharmaceuticals
Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II/III clinical trial to treat children and adolescent patients with fragile X syndrome; and is in Phase II clinical trial for treating children and adolescent patients with autism spectrum disorder.
Recommended Story: Book Value Of Equity Per Share – BVPS Explained
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.